WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

HUS Helsinki University Hospital is leading the research project on long-term effects of COVID-19

Details
Development
10 February 2023
Long COVID Project The EU has awarded a 6.55 million EUR funding to a HUS Helsinki University Hospital-led consortium to examine the mechanisms behind the long-term effects of a COVID-19 infection. The objective is also to create a Decision support system for prediction and management of Long Covid Syndrome (LCS).
Read more ...

The Nobel Prize in Physiology or Medicine 2022

Details
Development
03 October 2022
The Nobel Prize
The Nobel Assembly at Karolinska Institutet has today decided to award the 2022 Nobel Prize in Physiology or Medicine to Svante Pääbo for his discoveries concerning the genomes of extinct hominins and human evolution.
Read more ...

U.S. clinical trial evaluating antiviral for monkeypox begins

Details
Development
09 September 2022
A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. Study investigators aim to enroll more than 500 people from clinical research sites nationwide. Interested volunteers can visit the ACTG website (clinical trial A5418) for more information.
Read more ...

National science academies of the G7 states publish joint statement on the war in Ukraine

Details
Development
04 March 2022
The national science academies of the G7 states publish a joint statement on Russia's attack on Ukraine.

The science academies have been accompanying the annual meetings of the G7 states for more than 15 years. In the run-up to each summit, they address scientific agenda-related issues that require multilateral action.

Read more ...

WHO update on Omicron

Details
Development
29 November 2021
WHOOn 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO's Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE that Omicron has several mutations that may have an impact on how it behaves, for example, on how easily it spreads or the severity of illness it causes.
Read more ...

International Cancer Genome Consortium empowers cancer researchers everywhere with new cloud computing platform

Details
Development
24 November 2021
The International Cancer Genome Consortium (ICGC) is further enabling cancer research worldwide by making a massive collection of cancer data available for analysis via Microsoft's Azure cloud computing platform. Providing secure, controlled access to ICGC genomic and clinical data on Azure will mitigate the need for researchers to obtain massive amounts of storage and computing power within their home institutions, meaning that more researchers will be able to use the data.
Read more ...

Cleveland Clinic launches first-of-its kind preventive breast cancer vaccine study

Details
Development
01 November 2021
Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

This phase I trial is designed to determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer and to characterize and optimize the body's immune response.

Read more ...

More Pharma News ...

  1. COVID-19 vaccines have prevented 7.2 million infections and 27,000 deaths in England alone
  2. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations
  3. Africa urgently needs 20 million second doses of COVID-19 vaccine
  4. 60 million doses of COVID-19 vaccine administered in UK
  5. WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
  6. First COVID-19 COVAX vaccine doses administered in Africa
  7. COVAX announces new agreement, plans for first deliveries
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
  • Pfizer invests $43 billion to battle cancer

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Development
  4. COVAX announces new agreement, plans for first deliveries

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.